| Literature DB >> 33295021 |
Marcos Fragiel1, Òscar Miró2, Pere Llorens3, Sònia Jiménez2, Pascual Piñera4, Guillermo Burillo5, Alfonso Martín6, Francisco J Martín-Sánchez1, Eric J García-Lamberechts1, Javier Jacob7, Aitor Alquézar-Arbé8, Ricardo Juárez9, Blas Jiménez10, Rigoberto Del Rio11, Miriam Mateo Roca8, Arturo H García12, Nieves López Laguna13, María P Lopez Diez14, Jorge Pedraza García15, Amparo Fernández de Simón Almela16, Juan J Lopez Diaz17, Patricia Eiroa Hernández18, Noemí Ruiz de Lobera19, Jesús Porta-Etessam20, Cristina Fernández Pérez21, Elpidio Calvo22, Juan González Del Castillo1.
Abstract
We diagnosed 11 Guillain-Barré syndrome (GBS) cases among 71,904 COVID patients attended at 61 Spanish emergency departments (EDs) during the 2-month pandemic peak. The relative frequency of GBS among ED patients was higher in COVID (0.15‰) than non-COVID (0.02‰) patients (odds ratio [OR] = 6.30, 95% confidence interval [CI] = 3.18-12.5), as was the standardized incidence (9.44 and 0.69 cases/100,000 inhabitant-years, respectively, OR = 13.5, 95% CI = 9.87-18.4). Regarding clinical characteristics, olfactory-gustatory disorders were more frequent in COVID-GBS than non-COVID-GBS (OR = 27.59, 95% CI = 1.296-587) and COVID-non-GBS (OR = 7.875, 95% CI = 1.587-39.09) patients. Although COVID-GBS patients were more frequently admitted to intensive care, mortality was not increased versus control groups. Our results suggest SARS-CoV-2 could be another viral infection causing GBS. ANN NEUROL 2021;89:598-603.Entities:
Year: 2020 PMID： 33295021 DOI： 10.1002/ana.25987
Source DB: PubMed Journal: Ann Neurol ISSN： 0364-5134 Impact factor: 10.422